Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Harries, Lorna W ^a   Perry, John R B ^a   McCullagh, Paul ^b   Crundwell, Malcolm ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BETA MICROSEMINOPROTEIN; BINDING PROTEIN; CARBOXY TERMINAL BINDING PROTEIN 2; HNF HOMEOBOX 1 BETA; HOMEODOMAIN PROTEIN; JAZF ZINC FINGER 1; LEMUR TYROSINE KINASE 2; MESSENGER RNA; MICROSEMINOPROTEIN BETA 1; MICROSEMINOPROTEIN BETA 2; MYELOMA OVEREXPRESSED PROTEIN; ORGANIC CATION TRANSPORTER 3; PROTEIN MYEOV; PROTEIN TYROSINE KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; BETA-MICROSEMINOPROTEIN; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, HUMAN; ISOPROTEIN; LMTK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROSTATIC SECRETORY PROTEIN; PROTEIN SERINE THREONINE KINASE;

AGED; ALLELE; ARTICLE; CANCER HORMONE THERAPY; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; ADENOCARCINOMA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; MALE; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77953670889     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-315     Document Type: Article

References (37)

1. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996, 30(2):138-144.
2. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002, 168(3):906-913. 10.1016/S0022-5347(05)64541-7, 12187189.
3. Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, Corbishley C, Dorling D, Thomas B, Gillatt D, et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol 2008, 53(1):99-105. 10.1016/j.eururo.2007.02.047, 17368710.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7(4):256-269. 10.1038/nrc2090, 17384581.
5. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008, 98(2):502-507. 10.1038/sj.bjc.6604132, 2361443, 18182994.
6. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007, 99(24):1836-1844. 10.1093/jnci/djm250, 18073375.
7. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007, 39(8):977-983. 10.1038/ng2062, 17603485.
8. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40(3):310-315. 10.1038/ng.91, 18264096.
9. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40(3):316-321. 10.1038/ng.90, 18264097.
10. Ord T, Ord D, Koivomagi M, Juhkam K, Ord T. Human TRB3 is upregulated in stressed cells by the induction of translationally efficient mRNA containing a truncated 5'-UTR. Gene 2009, 444(1-2):24-32. 10.1016/j.gene.2009.06.001, 19505541.
11. Ishii H, Kobayashi M, Sakuma Y. Alternative promoter usage and alternative splicing of the rat estrogen receptor alpha gene generate numerous mRNA variants with distinct 5'-ends. J Steroid Biochem Mol Biol 2010, 118(1-2):59-69. 10.1016/j.jsbmb.2009.10.001, 19833204.
12. Welham SJ, Clark AJ, Salter AM. A novel liver specific isoform of the rat LAR transcript is expressed as a truncated isoform encoded from a 5'UTR located within intron 11. BMC Mol Biol 2009, 10:30. 10.1186/1471-2199-10-30, 2674045, 19356234.
13. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002, 3(4):285-298. 10.1038/nrg775, 11967553.
14. Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 2008, 1(1):37-42. 10.1242/dmm.000331, 2561970, 19048051.
15. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007, 8(4):349-357. 10.1016/S1470-2045(07)70104-3, 17395108.
16. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009, 6(8):454-460. 10.1038/nrurol.2009.125, 19657379.
17. Le Quesne JP, Spriggs KA, Bushell M, Willis AE. Dysregulation of protein synthesis and disease. J Pathol 2010, 220(2):140-51.
18. Chatterjee S, Pal JK. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 2009, 101(5):251-262. 10.1042/BC20080104, 19275763.
19. Chen JM, Ferec C, Cooper DN. A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006, 120(1):1-21. 10.1007/s00439-006-0180-7, 16645853.
20. Applied-Biosystems Relative quantitation of gene expression. User bulletin #2 2001, 11-15. Applied-Biosystems.
21. Harries LW, Bingham C, Bellanne-Chantelot C, Hattersley AT, Ellard S. The position of premature termination codons in the hepatocyte nuclear factor -1 beta gene determines susceptibility to nonsense-mediated decay. Hum Genet 2005, 118(2):214-224. 10.1007/s00439-005-0023-y, 16133182.
22. Harries LW, Wickham CL, Evans JC, Rule SA, Joyner MV, Ellard S. Analysis of haematopoietic chimaerism by quantitative real-time polymerase chain reaction. Bone Marrow Transplant 2005, 35(3):283-290. 10.1038/sj.bmt.1704764, 15531894.
23. Inoue T, Kon T, Ohkura R, Yamakawa H, Ohara O, Yokota J, Sutoh K. BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking. Genes Cells 2008, 13(5):483-495. 10.1111/j.1365-2443.2008.01184.x, 18429820.
24. Kawa S, Fujimoto J, Tezuka T, Nakazawa T, Yamamoto T. Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling. Genes Cells 2004, 9(3):219-232. 10.1111/j.1356-9597.2004.00714.x, 15005709.
25. Eto M, Elliott E, Prickett TD, Brautigan DL. Inhibitor-2 regulates protein phosphatase-1 complexed with NimA-related kinase to induce centrosome separation. J Biol Chem 2002, 277(46):44013-44020. 10.1074/jbc.M208035200, 12221103.
26. Kesavapany S, Lau KF, Ackerley S, Banner SJ, Shemilt SJ, Cooper JD, Leigh PN, Shaw CE, McLoughlin DM, Miller CC. Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase. J Neurosci 2003, 23(12):4975-4983.
27. Puri C, Chibalina MV, Arden SD, Kruppa AJ, Kendrick-Jones J, Buss F. Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 29(2):188-200. 10.1038/onc.2009.328, 19855435.
28. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007, 26(31):4590-4595. 10.1038/sj.onc.1210248, 17237810.
29. Hyakutake H, Sakai H, Yogi Y, Tsuda R, Minami Y, Yushita Y, Kanetake H, Nakazono I, Saito Y. Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993, 22(4):347-355. 10.1002/pros.2990220409, 8497429.
30. Ohnuma S, Miura K, Horii A, Fujibuchi W, Kaneko N, Gotoh O, Nagasaki H, Mizoi T, Tsukamoto N, Kobayashi T, et al. Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery 2009, 145(1):57-68. 10.1016/j.surg.2008.08.010, 19081476.
31. Harries L, Brown J, Gloyn AL. Species-specific differences in the expression of the HNF1A, HNF1B and HNF4A genes. PLoS One 2009, 4(11):e7855. 10.1371/journal.pone.0007855, 2773013, 19924231.
32. Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, Sonoda T, Akino K, Maruyama R, Nishiwara N, Imai K, et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J cancer 2006, 94(6):914-921. 10.1038/sj.bjc.6602984, 2361363, 16479257.
33. Rebouissou S, Vasiliu V, Thomas C, Bellane-Chantelot C, Bui H, Chretien Y, Timsit J, Rosty C, Laurent-Puig P, Chauveau D, et al. Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Human Molecular Genetics 2005, 14(5):603-614. 10.1093/hmg/ddi057, 15649945.
34. Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008, 40(10):1153-1155. 10.1038/ng.214, 18758462.
35. Bach I, Yaniv M. More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeoprotein family are generated by alternative RNA preocessing. The EMBO Journal 1993, 12(11):4229-4242. 413717, 7900999.
36. Romero L, Ng L, Kirby G. Chemical Inducers of Rodent Glutathione S-Transferases Down-Regulate Human GSTA1 Transcription through a Mechanism Involving Variant Hepatic Nuclear Factor 1-C. Mol Pharmacol 2006, 70(1):277-286.
37. Eiberg H, Troelsen J, Nielsen M, Mikkelsen A, Mengel-From J, Kjaer KW, Hansen L. Blue eye color in humans may be caused by a perfectly associated founder mutation in a regulatory element located within the HERC2 gene inhibiting OCA2 expression. Hum Genet 2008, 123(2):177-187. 10.1007/s00439-007-0460-x, 18172690.